Buyback yield (TTM)
N/A
Shareholder yield (TTM)
6.19%
5Y share count change
1.0%
Buyback spend (TTM)
N/A
Cumulative buybacks
$137.76B
Key takeaways
- Diluted share count is roughly flat (1.0%) over the last ~5 fiscal years — buybacks are offsetting dilution but not shrinking the float.
Dividend & buyback yield over time for Pfizer (PFE)
Stacked annual yields — buyback yield (TTM cash repurchases ÷ market cap) plus dividend yield from the same fiscal-year-end key-metrics period — show how total cash return per dollar of equity has evolved.
Diluted vs basic shares (annual) for Pfizer (PFE)
Diluted weighted-average shares are the EPS denominator — a falling count means buybacks are outpacing SBC dilution.
Year-over-year change in diluted shares for Pfizer (PFE)
Green is fewer shares vs the prior fiscal year (net repurchase); red is growth (dilution). The earliest year shown has no prior year to compare.
Cash buyback spend over time for Pfizer (PFE)
Latest: $0.00
Overview
In 2025, Pfizer (PFE) buyback spend totalled $0.00.
Across 2015–2025 (10 years), Pfizer buyback spend produced a CAGR of -100.0% – with a net decline across the window.
Pfizer buyback spend peaked at $16.29B in 2013; the latest annual figure is $0.00 in 2025 (100.0% below peak).
The record annual buyback spend stands at $16.29B, reached in 2013; the historical low of $0.00 was recorded in 2009.
Pfizer Buyback Spend 2025: $0.00
Pfizer buyback spend in 2025 was $0.00.
Pfizer Buyback Spend 2024: $0.00
Pfizer buyback spend in 2024 was $0.00.
Pfizer Buyback Spend 2023: $0.00
In 2023, Pfizer reported buyback spend of $0.00, plunged 100.0% below 2022.
Pfizer Buyback Spend 2022: $2.00B
Pfizer buyback spend in 2022 was $2.00B.
Pfizer Buyback Spend 2021: $0.00
Pfizer buyback spend in 2021 was $0.00.
See more financial history for Pfizer (PFE).
Buyback, SBC & dilution history
Buyback spend, SBC, net dilution effect, and share count.
| 2025 | $0.00 | $0.00 | $0.00 | — | 5.69B | -0.2% | |
| 2024 | $0.00 | $877.00M | −$877.00M | — | 5.70B | -0.2% | |
| 2023 | $0.00 | $525.00M | −$525.00M | — | 5.71B | -0.4% | |
| 2022 | $2.00B | $872.00M | $1.13B | 0.70% | 5.73B | +0.4% | |
| 2021 | $0.00 | $1.18B | −$1.18B | — | 5.71B | +1.3% | |
| 2020 | $0.00 | $756.00M | −$756.00M | — | 5.63B | -0.8% | |
| 2019 | $8.87B | $718.00M | $8.15B | 4.31% | 5.67B | -5.1% | |
| 2018 | $12.20B | $949.00M | $11.25B | 5.09% | 5.98B | -1.3% | |
| 2017 | $5.00B | $840.00M | $4.16B | 2.44% | 6.06B | -1.6% | |
| 2016 | $5.00B | $691.00M | $4.31B | 2.68% | 6.16B | -1.6% | |
| 2015 | $6.16B | $669.00M | $5.49B | 3.26% | 6.26B | -2.6% | |
| 2014 | $5.00B | $586.00M | $4.41B | 2.69% | 6.42B | -6.8% | |
| 2013 | $16.29B | $523.00M | $15.77B | 8.71% | 6.89B | -8.2% | |
| 2012 | $8.23B | $481.00M | $7.75B | 4.73% | 7.51B | -4.6% | |
| 2011 | $9.00B | $419.00M | $8.58B | 5.75% | 7.87B | -2.5% | |
| 2010 | $1.00B | $405.00M | $595.00M | 0.75% | 8.07B | +14.6% | |
| 2009 | $0.00 | $349.00M | −$349.00M | — | 7.04B | +4.4% | |
| 2008 | $500.00M | $0.00 | $500.00M | 0.44% | 6.75B | -2.7% | |
| 2007 | $9.99B | $0.00 | $9.99B | 6.84% | 6.94B | -4.6% | |
| 2006 | $6.98B | $0.00 | $6.98B | 3.98% | 7.27B | -1.8% | |
| 2005 | $3.80B | $0.00 | $3.80B | 2.34% | 7.41B | -2.7% | |
| 2004 | $6.66B | $0.00 | $6.66B | 3.50% | 7.61B | +4.5% | |
| 2003 | $13.04B | $0.00 | $13.04B | 5.13% | 7.29B | +16.7% | |
| 2002 | $5.00B | $0.00 | $5.00B | 2.82% | 6.24B | -1.9% | |
| 2001 | $3.67B | $0.00 | $3.67B | 1.56% | 6.36B | -0.1% | |
| 2000 | $1.00B | $0.00 | $1.00B | — | 6.37B | +0.8% | |
| 1999 | $2.54B | $0.00 | $2.54B | — | 6.32B | +60.4% | |
| 1998 | $2.18B | $0.00 | $2.18B | — | 3.94B | -0.3% | |
| 1997 | $586.00M | $0.00 | $586.00M | — | 3.95B | +2.4% | |
| 1996 | $27.00M | $0.00 | $27.00M | — | 3.86B | — | |
| 1995 | $108.50M | $0.00 | $108.50M | — | — | — | |
| 1994 | $511.20M | $0.00 | $511.20M | — | — | — | |
| 1993 | $1.02B | $0.00 | $1.02B | — | — | — | |
| 1992 | $665.10M | $0.00 | $665.10M | — | — | — | |
| 1991 | $463.90M | $0.00 | $463.90M | — | — | — | |
| 1990 | $132.20M | $0.00 | $132.20M | — | — | — | |
| 1989 | $154.70M | $0.00 | $154.70M | — | — | — |
- 2025$0.00
- 2024$0.00
- 2023$0.00
- 2022$2.00B
- 2021$0.00
- 2020$0.00
- 2019$8.87B
- 2018$12.20B
- 2017$5.00B
- 2016$5.00B
- 2015$6.16B
- 2014$5.00B
- 2013$16.29B
- 2012$8.23B
- 2011$9.00B
- 2010$1.00B
- 2009$0.00
- 2008$500.00M
- 2007$9.99B
- 2006$6.98B
- 2005$3.80B
- 2004$6.66B
- 2003$13.04B
- 2002$5.00B
- 2001$3.67B
- 2000$1.00B
- 1999$2.54B
- 1998$2.18B
- 1997$586.00M
- 1996$27.00M
- 1995$108.50M
- 1994$511.20M
- 1993$1.02B
- 1992$665.10M
- 1991$463.90M
- 1990$132.20M
- 1989$154.70M
Buybacks vs stock-based compensation for Pfizer (PFE)
Annual cash repurchases set against stock-based compensation. Coverage above 1× means buybacks fully offset the equity dilution from SBC. TTM coverage: 0.00×.
Buybacks vs dividends (share of cash returned) for Pfizer (PFE)
How Pfizer splits cash returned to shareholders between dividends and buybacks.
Sector peers by buyback spend
Companies in the same sector as Pfizer, ranked by their latest buyback spend.
| $5.95B | |
| $5.54B | |
| $5.08B | |
| $4.11B | |
| $980.00M | |
| $216.35M | |
| $0.00 | |
| $0.00 |
- $5.95B
- $5.54B
- $5.08B
- $4.11B
- $980.00M
- $216.35M
- $0.00
- $0.00
Buyback capacity (TTM)
Free cash flow minus dividends paid versus actual TTM repurchases — the headroom bar shows how much of post-dividend FCF is still being deployed elsewhere.
Headroom $0.00 (TTM FCF − TTM dividends, clamped at zero).
Frequently asked questions
Data & methodology
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation